Hannah Slater


Paving the Way to Modern Cancer Therapy

September 1st 2021

When George P. Canellos, MD, first joined the field of oncology in the 1960s, many of his peers thought he was making huge mistake.

Iomab-B/Transplant Causes Fewer AEs Versus Conventional Care in AML

February 11th 2021

February 11, 2021 - A conditioning regimen comprised of targeted radiation with Iomab-B led to a lower incidence of sepsis as well as trends toward reduced rates of severe mucositis and febrile neutropenia versus conventional care and standard conditioning regimens in older adults with relapsed or refractory acute myeloid leukemia.

Bemcentinib Plus Pembrolizumab Shows Clinical Activity in Advanced NSCLC

January 29th 2021

January 29, 2021 - The first-in-class oral kinase inhibitor bemcentinib, when used in combination with pembrolizumab, demonstrated clinical activity with favorable tolerability in patients with checkpoint inhibitor–naïve and CPI-refractory composite AXL–positive non–small cell lung cancer.

Pembrolizumab Plus Capecitabine/Bevacizumab Shows Favorable Tolerability in MSS mCRC

January 15th 2021

January 15, 2021 - Pembrolizumab (Keytruda) in combination with capecitabine and bevacizumab (Avastin) was found to show encouraging tolerability when used in patients with microsatellite stable (MSS) metastatic colorectal cancer (mCRC), according to data from a phase 2 trial (NCT03396926) presented during the 2020 Gastrointestinal Cancers Symposium.

Tucatinib Regimen Maintains Health-Related QoL in HER2+ Metastatic Breast Cancer

September 21st 2020

The addition of tucatinib to trastuzumab and capecitabine in patients with HER2-positive metastatic breast cancer with and without brain metastases resulted in statistically significant and clinically meaningful improvements in progression-free and overall survival.

Interim ZUMA-5 Analysis Shows Promise for Axi-Cel in Relapsed/Refractory iNHL

May 31st 2020

Axicabtagene ciloleucel (axi-cel; Yescarta) demonstrated significant and durable clinical benefit as well as a manageable safety profile in patients with relapsed or refractory indolent non-Hodgkin lymphoma.

HERO Trial Suggests Relugolix to Become New Standard for T-Suppression in Advanced Prostate Cancer

May 30th 2020

Relugolix (Relumina) demonstrated superiority over leuprolide (Lupron) in sustained testosterone (T)-suppression through 48 weeks in patients with advanced prostate cancer.

Phase II TheraP Trial Shows Promise for LuPSMA in mCRPC

May 29th 2020

Results from the TheraP trial found that in men with metastatic castration resistant prostate cancer who progressed after treatment with docetaxel, 177Lu-PSMA-617 was more active than cabazitaxel.

Novel Antibody-Drug Conjugates Show Encouraging Activity in TNBC

March 7th 2020

Novel antibody-drug conjugates have demonstrated high response rates in patients with heavily pretreated metastatic breast cancer, and ongoing studies targeting actionable cell-surface markers may further expand their clinical utility, according to Aditya Bardia, MD, MPH.